title: Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome.
abstract: To evaluate the efficacy of a terpene mixture (rowatinex) compared to ibuprofen, patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) were randomly selected to either receive rowatinex 200 mg t.i.d. or ibuprofen 600 mg t.i.d. After a 6-week treatment, the decrease in the mean total NIH-CPSI score was significant in both groups from 21.4 to 15.3, (6.1 (p < 0.01) and from 21.2 to 16.8, (4.4 (p = 0.04) in the rowatinex and ibuprofen group, respectively. The rate of definite improvement as defined as 25% improvement in the total score was superior (p = 0.04) in the rowatinex group (68%) versus the ibuprofen group (40%). Judging from these results, rowatinex gave significant symptomatic relief and may be of benefit for many men diagnosed with CP/CPPS. Further, including the placebo-controlled studies are necessary to define its role in the management of this difficult to treat disease.
authors.affiliation: Department of Urology, St. Vincent Hospital, Catholic University College of Medicine, Suwon, Korea.
authors.forename: Choong Bum
authors.initials: CB
authors.lastname: Lee
authors.forename: U-Syn
authors.initials: US
authors.lastname: Ha
authors.forename: Seung Ju
authors.initials: SJ
authors.lastname: Lee
authors.forename: Sae Woong
authors.initials: SW
authors.lastname: Kim
authors.forename: Yong-Hyun
authors.initials: YH
authors.lastname: Cho
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006305:Health Status Indicators; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage*; D008297:Male; D017699:Pelvic Pain / Q000175:diagnosis / Q000188:drug therapy*; D011336:Probability; D011472:Prostatitis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013577:Syndrome; D013729:Terpenes / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D013729:Terpenes; C036965:Rowatinex; D007052:Ibuprofen